Menu
Search

News

Swiss Deep Tech News & Analysis

Stay informed on the Swiss technology landscape. This is your central resource for Deep Tech News, combining key developments from across the ecosystem with original, data-driven analysis from the Deep Tech Nation Foundation. We track and report on significant technological milestones, funding rounds, and research to provide a comprehensive overview for international investors, partners, and researchers.

Curated Newsfeed

See all news

DTN Highlights

See DTN Highlights

  • Spanish travel-tech unicorn acquires Yokoy

    Yokoy, the leading spend management platform, has been acquired by TravelPerk, a business travel platform based in Barcelona. In parallel, TravelPerk announced the closing of…

    startupticker.ch

    • TravelPerk acquired Yokoy, an AI-powered expense management platform, in an all-equity deal valued at $2.7 billion.
    • TravelPerk raised $200M in Series E funding led by Atomico and EQT Growth, achieving profitability with $200M+ annualized revenue.
    • The combined company will integrate travel and expense management to help customers reduce costs and streamline processes.
    startupticker.ch: Spanish travel-tech unicorn acquires Yokoy

  • AB2 Bio signs USD 600 million agreement with Nippon Shinyaku

    AB2 Bio Ltd., developing therapies for the treatment of severe systemic hyperinflammatory diseases and conditions driven by IL-18, has entered into an option and licensing…

    startupticker.ch

    • AB2 Bio partnered with Nippon Shinyaku to develop Tadekinig alfa for Primary Monogenic IL-18 driven Hyperinflammatory Syndrome.
    • AB2 Bio receives up to $686 million in total payments, including $36 million upfront and $150 million in milestones.
    • Tadekinig alfa is a novel IL-18 binding protein for rare pediatric disease with no current FDA-approved treatment.
    startupticker.ch: AB2 Bio signs USD 600 million agreement with Nippon Shinyaku

  • ZuriQ secures $4.2M seed funding to break quantum computing's scaling barrier

    Quantum computing startup ZuriQ has today announced the closing of its $4.2 million seed funding round to commercialize a radical new architecture that will enable scaling…

    startupticker.ch

    • ZuriQ raised $4.2M seed funding to scale trapped-ion quantum computers using 2D ion grids instead of 1D chains, solving a key scalability problem.
    • ZuriQ plans to demonstrate a prototype with dozens of ions in a 2D grid by late 2024, targeting thousands of qubits for practical quantum computing.
    startupticker.ch: ZuriQ secures $4.2M seed funding to break quantum computing's scaling barrier

  • Transmutex receives $4 million grant to enable nuclear waste transmutation

    Geneva-based startup Transmutex has received more than $4.2 million from the U.S. Department of Energy Advanced Research Projects Agency-Energy as part of the NEWTON Program.…

    startupticker.ch

    • Transmutex received $4.2M from the U.S. Department of Energy to develop nuclear waste transmutation technology reducing hazardous lifetime from 1 million to a few hundred years.
    startupticker.ch: Transmutex receives $4 million grant to enable nuclear waste transmutation

  • Tech Tour Growth Top 50 showcases Swiss deeptech companies

    Switzerland is a hub of innovation, home to numerous trailblazing startups, including six that have earned a spot in the Tech Tour Growth Top 50…

    startupticker.ch

    • Six Swiss startups made the 2025 Tech Tour Growth50 list, with four securing over $20 million in funding.
    • Swiss companies like ANYbotics, Lakera AI, and DistalMotion lead in robotics, AI security, and surgical innovation.
    • International investors increasingly fund European tech leaders, challenging US dominance in attracting global investment.
    startupticker.ch: Tech Tour Growth Top 50 showcases Swiss deeptech companies

  • BioVersys to go public at SIX Swiss Exchange

    BioVersys develops novel antibacterial products for serious life-threatening infections caused by multidrug-resistant bacteria. The Basel-based company plans to conduct an initial public offering on the…

    startupticker.ch

    • BioVersys plans Q1 2025 IPO on SIX Swiss Exchange, targeting CHF 80M for BV100 Phase 3 development.
    • BV100 treats carbapenem-resistant Acinetobacter baumannii (50% mortality); Alpibectir targets TB.
    • GSK and AMR Action Fund, existing shareholders, committed to additional IPO investment.
    startupticker.ch: BioVersys to go public at SIX Swiss Exchange

  • Swiss startups strengthen presence in North America

    With the establishment of their new offices in the US, Attolight, Blocksport and NewBiologix, aim to increase proximity to customers in the North American market,…

    startupticker.ch

    • Attolight, Blocksport, and NewBiologix opened U.S. offices to expand customer relationships and North American market presence.
    • Blocksport launched a New York hub for sports fan engagement platforms and digital collectibles for North American clubs.
    • NewBiologix formed a U.S. subsidiary offering gene and cell therapy support, including its Xcell Portfolio for viral vector analysis.
    startupticker.ch: Swiss startups strengthen presence in North America

  • RhyGaze raises USD 86 million to advance gene therapy for retinal diseases

    Based in Basel and Philadelphia, USA, RhyGaze has secured a Series A financing of USD 86 million to enable clinical advancements for its lead candidate,…

    startupticker.ch

    • RhyGaze secured $86M Series A funding from Google Ventures for gene therapy to restore vision in blindness.
    • The technology aims to restore high-acuity vision by repairing cone cells in retinal diseases.
    • Funding supports preclinical testing, observational studies, and a first-in-human clinical trial.
    startupticker.ch: RhyGaze raises USD 86 million to advance gene therapy for retinal diseases

  • Sygnum achieves unicorn status with USD 58m growth round

    Global digital asset banking group Sygnum has raised a total of USD 58 million in its oversubscribed Strategic Growth Round, giving it a post-money valuation…

    startupticker.ch

    • Sygnum raised $58M in a strategic round, achieving unicorn status with $1B+ valuation and $5B in client assets.
    • Sygnum achieved profitability in 2024 with 1,000%+ YoY trade growth, driven by B2B partnerships serving over one-third of Switzerland.
    • Sygnum plans EU/EEA and Hong Kong expansion, focusing on Bitcoin products and strengthening compliance infrastructure.
    startupticker.ch: Sygnum achieves unicorn status with USD 58m growth round

  • Windward Bio launches with $200 million Series A financing round

    Founded by serial entrepreneur Luca Santarelli, Windward Bio has just launched with a $200 million capital injection. These funds will accelerate clinical advancements in programs…

    startupticker.ch

    • Windward Bio raised $200M Series A to develop WIN378, a monoclonal antibody for severe asthma and COPD dosed every six months.
    • WIN378 targets TSLP ligand to treat ~5M patients with advanced, uncontrolled asthma/COPD in US, Europe, and Japan.
    • Windward Bio's founding team contributed to 15+ product launches, 2 Nasdaq IPOs, and 2 strategic exits.
    startupticker.ch: Windward Bio launches with $200 million Series A financing round

  • ONWARD Medical wins first commercial customers in the US

    With the first commercial sale of the ARC-EX System in the US, ONWARD Medical has reached a key milestone in its journey to provide innovative…

    startupticker.ch

    • ONWARD Medical's ARC-EX System is FDA-approved to improve hand strength and sensation in spinal cord injury patients via electrical stimulation.
    • The device received FDA de novo classification on December 19, 2024, with first sales at UW Medicine and Next Steps Chicago.
    • ONWARD plans home use authorization in 2025, European CE Mark certification, and implantable alternatives including brain-computer interfaces.
    startupticker.ch: ONWARD Medical wins first commercial customers in the US

  • Numab raises additional CHF50 million

    Numab Therapeutics, a clinical stage biotechnology company focusing on multi-specific antibodies in immunology and oncology, closed an oversubscribed CHF 50 million Series C extension, bringing…

    startupticker.ch

    • Numab Therapeutics raised CHF 50 million in Series C extension funding, bringing total Series C to CHF 180 million.
    • Johnson & Johnson's 2024 acquisition of Numab spin-out Yellow Jersey for $1.25 billion validated the platform.
    • Funding will advance clinical and pre-clinical multi-specific antibodies for inflammation and oncology.
    startupticker.ch: Numab raises additional CHF50 million